<p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）首席执行官 Daniel Joseph Oconnell 于 1 月 6 日星期二出售了 5,102 股该公司的股票。股票以平均价格 1.97 美元出售，总价值为 10,050.94 美元。交易完成后，首席执行官在公司中持有 657,737 股，价值约为 1,295,741.89 美元。这笔交易代表了他们持股比例的 0.77% 的减少。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。</p>
<p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周报 – 7/17 - 7/21</li>
</ul>
<p>Daniel Joseph Oconnell 最近还进行了以下交易：</p>
<ul>
<li>在 1 月 7 日星期三，Daniel Joseph Oconnell 出售了 37,755 股 Acumen Pharmaceuticals 的股票。这些股票以平均价格 1.99 美元出售，总价值为 75,132.45 美元。</li>
<li>在 1 月 5 日星期一，Daniel Joseph Oconnell 出售了 4,649 股 Acumen Pharmaceuticals 的股票。这些股票以平均价格 1.97 美元出售，总价值为 9,158.53 美元。</li>
</ul>
<h2>Acumen Pharmaceuticals 股票表现</h2>
<p>在星期三的午盘交易中，纳斯达克 ABOS 的股票上涨了 0.03 美元，达到了 1.99 美元。该公司共交易了 220,171 股股票，而其平均交易量为 159,170 股。该公司的 50 日移动平均为 1.96 美元，200 日移动平均为 1.67 美元。Acumen Pharmaceuticals, Inc.的 1 年最低价为 0.86 美元，1 年最高价为 2.46 美元。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。该股票的市值为 1.2053 亿美元，市盈率为-0.90，贝塔值为 0.23。</p>
<ul>
<li>Acumen 因阿尔茨海默病研究而飙升……市场预期其股价翻倍</li>
</ul>
<p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近于 11 月 12 日星期三发布了季度财报。公司报告每股收益为（0.44 美元），超出市场共识预期的（0.63 美元）0.19 美元。分析师平均预测 Acumen Pharmaceuticals, Inc.在当前年度的每股收益为-1.56 美元。</p>
<h2>华尔街分析师观点</h2>
<p>ABOS 最近成为多份分析师报告的主题。Weiss Ratings 在 10 月 14 日星期二的研究报告中重申了对 Acumen Pharmaceuticals 股票的 “卖出（d-）” 评级。Wall Street Zen 在 12 月 21 日星期日的报告中将 Acumen Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。最后，美国银行在 11 月 18 日星期二的研究报告中将 Acumen Pharmaceuticals 的目标价从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 6.75 美元。</p>
<p><strong>查看我们对 ABOS 的最新分析</strong></p>
<h2>Acumen Pharmaceuticals 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Jacobs Levy Equity Management Inc.在第三季度购买了 Acumen Pharmaceuticals 的新股份，价值 27,000 美元。Marex Group plc 在第二季度购买了 Acumen Pharmaceuticals 的新股份，价值 39,000 美元。AQR Capital Management LLC 在第一季度购买了 Acumen Pharmaceuticals 的新股份，价值 46,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 现在拥有 57,559 股该公司的股票，价值 67,000 美元，此前在上个季度增持了 35,424 股。最后，Invesco Ltd.在第一季度将其在 Acumen Pharmaceuticals 的持股增加了 544.1%。Invesco Ltd.现在拥有 127,798 股该公司的股票，价值 141,000 美元，此前在此期间增持了 107,956 股。对冲基金和其他机构投资者持有该公司 71.01% 的股份。</p>
<h2>更多 Acumen Pharmaceuticals 新闻</h2>
<p>以下是本周影响 Acumen Pharmaceuticals 的主要新闻：</p>
<ul>
<li>中性情绪：文件中未说明原因——披露显示常规的 Form 4 销售，但未解释交易是否是预先计划的或出于个人流动性/多样化；这种模糊性使市场解读开放。</li>
<li>消极情绪：首席执行官 Daniel Joseph O'Connell 在 1 月 5 日至 7 日之间共出售了 47,506 股（单笔交易为 4,649；5,102；和 37,755 股），获得约 94,300 美元的收益；最大单笔交易（37,755 股）被报告为其持股减少了 5.74%。阅读更多。</li>
<li>消极情绪：首席财务官 Matt Zuga 在 1 月 5 日至 7 日之间出售了 14,905 股（4,000；5,100；5,805），总收益约为 29,400 美元，单笔交易持股减少幅度较小（1.73%–2.61%）。阅读更多。</li>
<li>消极情绪：首席运营官 Russell Barton 在 1 月 5 日至 7 日之间出售了 9,318 股（4,000；3,618；1,700），获得约 18,400 美元的收益，持股减少幅度较小（1.32%–2.94%）。阅读更多。</li>
<li>消极情绪：内部人士 Eric Siemers 在 1 月 5 日至 6 日之间出售了 10,834 股（4,000；6,834），获得约 21,300 美元的收益，报告的持股减少幅度为～2.35%–4.11% 每笔交易。阅读更多。</li>
</ul>
<h2>关于 Acumen Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发用于神经退行性疾病的口服小分子疗法。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学。</p>
<p>该公司的产品线包括多个在不同阶段的临床前和早期临床开发的领先候选药物。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Acumen Pharmaceuticals 更好的股票</li>
<li>Elon 正在将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话？看看接下来会发生什么。</li>
<li>这只股票获得了 94 分（满分 100 分）</li>
<li>将这些代码输入到你的普通经纪账户中</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Acumen Pharmaceuticals 吗？</h2>
<p>在考虑投资 Acumen Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Acumen Pharmaceuticals 并不在名单上。</p>
<p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABOS

<p>Acumen Pharmaceuticals 首席执行官 Daniel Joseph Oconnell 以每股 1.97 美元的价格出售了 5,102 股，总计 10,050.94 美元，减少了 0.77% 的持股比例。出售后，他持有 657,737 股，价值约 130 万美元。此交易已向美国证券交易委员会（SEC）披露。Oconnell 最近还以 1.99 美元的价格出售了 37,755 股，以 1.97 美元的价格出售了 4,649 股。Acumen 的股票目前交易价格为 1.99 美元，市值为 1.2053 亿美元，市盈率为 -0.90。分析师对该股票的评级不一，平均目标价为 6.75 美元</p>

<p>Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 5,102 shares of the firm's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $1.97, for a total value of $10,050.94. Following the completion of the transaction, the chief executive officer owned 657,737 shares in the company, valued at approximately $1,295,741.89. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）首席执行官 Daniel Joseph Oconnell 于 1 月 6 日星期二出售了 5,102 股该公司的股票。股票以平均价格 1.97 美元出售，总价值为 10,050.94 美元。交易完成后，首席执行官在公司中持有 657,737 股，价值约为 1,295,741.89 美元。这笔交易代表了他们持股比例的 0.77% 的减少。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。</p>
</div><p>Get <strong>Acumen Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 7/17 - 7/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 7/17 - 7/21</li>
</ul>
</div><p>Daniel Joseph Oconnell also recently made the following trade(s):</p>
<div class="lb-trans"><p>Daniel Joseph Oconnell 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.99, for a total value of $75,132.45.</li>
<li>On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $9,158.53.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 7 日星期三，Daniel Joseph Oconnell 出售了 37,755 股 Acumen Pharmaceuticals 的股票。这些股票以平均价格 1.99 美元出售，总价值为 75,132.45 美元。</li>
<li>在 1 月 5 日星期一，Daniel Joseph Oconnell 出售了 4,649 股 Acumen Pharmaceuticals 的股票。这些股票以平均价格 1.97 美元出售，总价值为 9,158.53 美元。</li>
</ul>
</div><h2>Acumen Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 股票表现</h2>
</div><p>Shares of NASDAQ ABOS traded up $0.03 during midday trading on Wednesday, hitting $1.99. 220,171 shares of the company's stock traded hands, compared to its average volume of 159,170. The firm has a fifty day moving average of $1.96 and a 200 day moving average of $1.67. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The stock has a market capitalization of $120.53 million, a price-to-earnings ratio of -0.90 and a beta of 0.23.</p>
<div class="lb-trans"><p>在星期三的午盘交易中，纳斯达克 ABOS 的股票上涨了 0.03 美元，达到了 1.99 美元。该公司共交易了 220,171 股股票，而其平均交易量为 159,170 股。该公司的 50 日移动平均为 1.96 美元，200 日移动平均为 1.67 美元。Acumen Pharmaceuticals, Inc.的 1 年最低价为 0.86 美元，1 年最高价为 2.46 美元。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。该股票的市值为 1.2053 亿美元，市盈率为-0.90，贝塔值为 0.23。</p>
</div><ul>
<li>Acumen Soars on Alzheimer's Study...Street Sees It Doubling</li>
</ul>
<div class="lb-trans"><ul>
<li>Acumen 因阿尔茨海默病研究而飙升……市场预期其股价翻倍</li>
</ul>
</div><p>Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. On average, analysts forecast that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近于 11 月 12 日星期三发布了季度财报。公司报告每股收益为（0.44 美元），超出市场共识预期的（0.63 美元）0.19 美元。分析师平均预测 Acumen Pharmaceuticals, Inc.在当前年度的每股收益为-1.56 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>ABOS has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Acumen Pharmaceuticals in a research report on Tuesday, October 14th. Wall Street Zen raised Acumen Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, December 21st. Finally, Bank of America lowered their price objective on Acumen Pharmaceuticals from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 18th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $6.75.</p>
<div class="lb-trans"><p>ABOS 最近成为多份分析师报告的主题。Weiss Ratings 在 10 月 14 日星期二的研究报告中重申了对 Acumen Pharmaceuticals 股票的 “卖出（d-）” 评级。Wall Street Zen 在 12 月 21 日星期日的报告中将 Acumen Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。最后，美国银行在 11 月 18 日星期二的研究报告中将 Acumen Pharmaceuticals 的目标价从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 6.75 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ABOS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ABOS 的最新分析</strong></p>
</div><h2>Institutional Trading of Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. bought a new stake in Acumen Pharmaceuticals in the third quarter worth $27,000. Marex Group plc purchased a new stake in shares of Acumen Pharmaceuticals in the second quarter valued at $39,000. AQR Capital Management LLC purchased a new stake in shares of Acumen Pharmaceuticals in the first quarter valued at $46,000. Qube Research &amp; Technologies Ltd lifted its holdings in shares of Acumen Pharmaceuticals by 160.0% in the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 57,559 shares of the company's stock worth $67,000 after acquiring an additional 35,424 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Acumen Pharmaceuticals by 544.1% during the 1st quarter. Invesco Ltd. now owns 127,798 shares of the company's stock worth $141,000 after purchasing an additional 107,956 shares during the period. Hedge funds and other institutional investors own 71.01% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Jacobs Levy Equity Management Inc.在第三季度购买了 Acumen Pharmaceuticals 的新股份，价值 27,000 美元。Marex Group plc 在第二季度购买了 Acumen Pharmaceuticals 的新股份，价值 39,000 美元。AQR Capital Management LLC 在第一季度购买了 Acumen Pharmaceuticals 的新股份，价值 46,000 美元。Qube Research &amp; Technologies Ltd 在第二季度将其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 现在拥有 57,559 股该公司的股票，价值 67,000 美元，此前在上个季度增持了 35,424 股。最后，Invesco Ltd.在第一季度将其在 Acumen Pharmaceuticals 的持股增加了 544.1%。Invesco Ltd.现在拥有 127,798 股该公司的股票，价值 141,000 美元，此前在此期间增持了 107,956 股。对冲基金和其他机构投资者持有该公司 71.01% 的股份。</p>
</div><h2>More Acumen Pharmaceuticals News</h2>
<div class="lb-trans"><h2>更多 Acumen Pharmaceuticals 新闻</h2>
</div><p>Here are the key news stories impacting Acumen Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响 Acumen Pharmaceuticals 的主要新闻：</p>
</div><ul>
<li>Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.</li>
<li>Negative Sentiment: CEO Daniel Joseph O'Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.</li>
<li>Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.</li>
<li>Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.</li>
<li>Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>中性情绪：文件中未说明原因——披露显示常规的 Form 4 销售，但未解释交易是否是预先计划的或出于个人流动性/多样化；这种模糊性使市场解读开放。</li>
<li>消极情绪：首席执行官 Daniel Joseph O'Connell 在 1 月 5 日至 7 日之间共出售了 47,506 股（单笔交易为 4,649；5,102；和 37,755 股），获得约 94,300 美元的收益；最大单笔交易（37,755 股）被报告为其持股减少了 5.74%。阅读更多。</li>
<li>消极情绪：首席财务官 Matt Zuga 在 1 月 5 日至 7 日之间出售了 14,905 股（4,000；5,100；5,805），总收益约为 29,400 美元，单笔交易持股减少幅度较小（1.73%–2.61%）。阅读更多。</li>
<li>消极情绪：首席运营官 Russell Barton 在 1 月 5 日至 7 日之间出售了 9,318 股（4,000；3,618；1,700），获得约 18,400 美元的收益，持股减少幅度较小（1.32%–2.94%）。阅读更多。</li>
<li>消极情绪：内部人士 Eric Siemers 在 1 月 5 日至 6 日之间出售了 10,834 股（4,000；6,834），获得约 21,300 美元的收益，报告的持股减少幅度为～2.35%–4.11% 每笔交易。阅读更多。</li>
</ul>
</div><h2>About Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Acumen Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于发现和开发用于神经退行性疾病的口服小分子疗法。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学。</p>
</div><p>The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.</p>
<div class="lb-trans"><p>该公司的产品线包括多个在不同阶段的临床前和早期临床开发的领先候选药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Acumen Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>This stock gets a 94 out of 100</li>
<li>Punch these codes into your ordinary brokerage account</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Acumen Pharmaceuticals 更好的股票</li>
<li>Elon 正在将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话？看看接下来会发生什么。</li>
<li>这只股票获得了 94 分（满分 100 分）</li>
<li>将这些代码输入到你的普通经纪账户中</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acumen Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Acumen Pharmaceuticals 吗？</h2>
</div><p>Before you consider Acumen Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Acumen Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Acumen Pharmaceuticals 并不在名单上。</p>
</div><p>While Acumen Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Acumen Pharmaceuticals（纳斯达克股票代码：ABOS）的首席执行官 Daniel Joseph Oconnell 出售了 5,102 股股票